152712-44-2

Basic information

• Product Name: ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate
• Synonyms: ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate;ethyl 3-(3,4-dihydro-2H-quinolin-1-yl)-2-oxo-propanoate
• CAS NO: 152712-44-2
• Molecular Formula: C₁₄H₁₇NO₃
• Molecular Weight: 247.28968
• EINECS: -0
• Mol File: 152712-44-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate(152712-44-2)
• EPA Substance Registry System: ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate(152712-44-2)

Safety Data

• Hazardous Substances Data: 152712-44-2(Hazardous Substances Data)

Usage

Description

Ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate is a chemical compound that belongs to the ester class and is a derivative of the dihydroquinoline ring, a heterocyclic aromatic compound. It is characterized by an ethyl ester group, a ketone group, and a dihydroquinoline ring, which confer unique properties and reactivity to the molecule. ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate may be of interest to researchers and industries in the fields of chemical synthesis, pharmaceuticals, and materials science due to its potential applications in organic synthesis and medicinal chemistry.

Uses

Used in Organic Synthesis:
Ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate is used as a synthetic intermediate for the preparation of various organic compounds. Its unique molecular structure allows for versatile reactivity, making it a valuable building block in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
Ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate is used as a potential lead compound in the development of new pharmaceuticals. Its dihydroquinoline ring is a common structural motif in many bioactive molecules, and its ethyl ester and ketone groups can be further modified to explore its potential as a therapeutic agent.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate is used as a key component in the synthesis of drugs targeting various diseases. Its unique properties and reactivity enable the development of novel drug candidates with improved efficacy and selectivity.
Used in Materials Science:
Ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)-2-oxopropanoate may also find applications in materials science, where its unique molecular structure can be utilized to develop new materials with specific properties. For example, it could be used in the synthesis of organic materials with potential applications in electronics, sensors, or other advanced technologies.

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 70-23-5 ethyl Bromopyruvate 
• 856703-29-2 2-cyclopentyl-1, 2,3, 4-tetrahydroquinoline 

Downstream Products

• 905854-06-0 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(3-methoxyphenyl)pyrrole-2,5-dione 
• 1000873-98-2 (±)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 1000873-98-2 (±)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 345261-20-3 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dion 
• 345264-02-0 (5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)oxoacetic acid methyl ester 
• 1000873-98-2 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 905854-03-7 (+)-3(S),4(S)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-j]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 905854-02-6 Tivantinib 
• 1000873-98-2 3(S),4(R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 1000873-98-2 tivatinib 
• 905854-16-2 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(2-chloro-4-fluorophenyl)pyrrole-2,5-dione 
• 124730-56-9 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-carboxylic acid 
• 5840-01-7 5,6-dihydro-4H-pyrrolo-[3,2,1-ij]quinoline 
• 124730-53-6 5,6-dihydro-4H-pyrrolo [3,2,1-ij]quinoline-1-carboxylic acid ethyl ester 

Relevant articles and documents

COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.

TRICYCLIC 1-[(3-INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS

The invention relates to tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula (I) wherein X is CH2, O or S; R represents 1-3 substituents independently selected from H, (C1-4)alkyl, (C1-4)alky

Development of high-affinity 5-HT3 receptor antagonists. Structure- affinity relationships of novel 1,7-annelated indole derivatives. 1

On the basis of the structures of ondansetron and GR 65,630, its ring- opened C-linked methylimidazole analogue, novel 1,7-annelated indole derivatives were synthesized as potential 5-HT3 antagonists. Receptor binding studies show that all compounds display a high affinity for the 5- HT3 receptors. In both series annelation results in compounds being 7 and 4 times more potent than the references ondansetron and GR 65,630, respectively. Similar to ondansetron, the 1,7-annelated indoles show little stereoselectivity. The (-)-isomers are only slightly more potent than the (+)-isomers. The receptor binding profile of l-10-[(2-methyl-1H-imidazol-1- yl)methyl]-5,6,8,9,10,11-hexahydro-4H-pyrido[3,2,1-jk]carbazol-11-one hydrochloride (24b) (INN cilansetron) shows that the compound displays, besides a high affinity for 5-HT3 receptors (K(i) = 0.19 nM), a weak affinity for σ-receptors (K(i) = 340 nM), muscarine M1 receptors (K(i) = 910 nM), and 5-HT4 receptors (K(i) = 960 nM) and no affinity (K(i) ≥ 5000 nM) for all the other receptor types tested (n = 37). The new compounds fit the proposed necessary chemical template for binding: a heteroaromatic ring system, a coplanar carbonyl group, and a nitrogen center at well-defined distances. The enhanced potency of the annelated 1,7-indole derivatives indicates that the extra ring provides a favorable hydrophobic area for interaction with the 5-HT3 receptor site. In vivo cilansetron is more potent and induces less central side effects than ondansetron. At present cilansetron is in clinical trials.